After nearly 50 years of research and development, oligonucleotide therapeutics are starting to make their mark on the pharmaceutical scene. Over the next several years, the market is poised to grow significantly, with 16 oligonucleotide drugs approved in Japan in 2022.

As interest in therapeutic oligonucleotides accelerates, manufacturers and researchers are working to identify and develop processes that address the significant environmental burdens of oligonucleotide manufacturing while saving resources and improving scalability.

FILL OUT FORM TO DOWNLOAD THE WHITE PAPER >>>>>